Findings on Rotavirus from V. Hoffman and Colleagues Provide New Insights (Validation of current procedural terminology codes for rotavirus…

Findings on Rotavirus from V. Hoffman and Colleagues Provide New Insights (Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Rotavirus. According to news originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, "We validated procedure codes used in health insurance claims for reimbursement of rotavirus vaccination by comparing claims for monovalent live-attenuated human rotavirus vaccine (RV1) and live, oral pentavalent rotavirus vaccine (RV5) to medical records. Using administrative data from two commercially insured United States populations, we randomly sampled vaccination claims for RV1 and RV5 from a cohort of infants aged less than 1 year from an ongoing post-licensure safety study of rotavirus vaccines."

Our news journalists obtained a quote from the research, "The codes for RV1 and RV5 found in claims were confirmed through medical record review. The positive predictive value (PPV) of the Current Procedural Terminology codes for RV1 and RV5 was calculated as the number of medical record-confirmed vaccinations divided by the number of medical records obtained. Medical record review confirmed 92 of 104 RV1 vaccination claims (PPV: 88.5%; 95% CI: 80.7-93.9%) and 98 of 113 RV5 vaccination claims (PPV: 86.7%; 95% CI: 79.1-92.4%). Among the 217 medical records abstracted, only three (1.4%) of vaccinations were misclassified in claims-all were RV5 misclassified as RV1. The medical records corresponding to 9 RV1 and 15 RV5 claims contained insufficient information to classify the type of rotavirus vaccine. Misclassification of rotavirus vaccines is infrequent within claims."

According to the news editors, the research concluded: "The PPVs reported here are conservative estimates as those with insufficient information in the medical records were assumed to be incorrectly coded in the claims."

For more information on this research see: Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations. Pharmacoepidemiology and Drug Safety, 2016;25(12):1465-1469. Pharmacoepidemiology and Drug Safety can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Pharmacoepidemiology and Drug Safety - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-1557)

The news correspondents report that additional information may be obtained from V. Hoffman, Optum Epidemiol, Ann Arbor, MI 48108, United States. Additional authors for this research include N.J. Everage, S.C. Quinlan, K. Skerry, D. Esposito, N. Praet, D. Rosillon, C.N. Holick and D.D. Dore (see also Rotavirus).

Keywords for this news article include: Ann Arbor, Michigan, United States, North and Central America, Medical Records, Drugs and Therapies, Epidemiology, Biological Products, Records as Topic, Public Health, Immunization, Vaccination, RNA Viruses, Reoviridae, Rotavirus, Vaccines, Virology, Viral.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC